Form 4: Dyne Therapeutics Chief Medical Officer Wildon Farwell Sells Shares
SEC Form 4 Filing
Wildon Farwell, Chief Medical Officer of Dyne Therapeutics, sold 407 shares of common stock at $25 per share on February 28, 2024, according to a Form 4 filing with the SEC.
Summary
- On February 28, 2024, Wildon Farwell, the Chief Medical Officer of Dyne Therapeutics, sold 407 shares of common stock.
- The sale was executed at a price of $25 per share.
- This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on July 14, 2023.
- Following the transaction, Farwell still beneficially owns 163,096 shares, which includes 140,510 unvested Restricted Stock Units (RSUs).
Sentiment
Score: 5
Explanation: The sentiment is neutral as it's a standard disclosure of an insider stock sale under a pre-existing trading plan. It doesn't inherently indicate positive or negative news about the company.
Industry Context
This filing is a routine disclosure of insider trading activity. It's common for executives to have pre-arranged trading plans to sell shares over time.
Stakeholder Impact
- The sale of shares by a high-ranking officer could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| July 14, 2023 | Date the Reporting Person adopted a Rule 10b5-1 trading plan |
| February 28, 2024 | Date of the stock sale transaction |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.